Trial reportBlood cancer journal2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.Frontiers in oncology · 2023Pooled it
- Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.Blood cancer journal · 2025Trial
- Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study.Annals of hematology · 2026Article
- Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.Annals of hematology · 2025Article
- Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study).Frontiers in oncology · 2025Article
- Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.Clinical and experimental medicine · 2024Article
- Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.Annals of hematology · 2024Article
- MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging and disease · 2024Review
- Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.Oncology and therapy · 2022Review
- Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?Cells · 2022Review
- Experts' consensus on the definition and management of high risk multiple myeloma.Frontiers in oncology · 2022Review
- Role of Stem Cell Transplantation in Multiple Myeloma.Cancers · 2021Review
- The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.